scholarly journals A case of thrombotic thrombocytopenic purpura which was successfully treated with rituximab and cyclophosphamide in addition to plasma exchange and high-dose steroid therapy

2015 ◽  
Vol 48 (10) ◽  
pp. 593-597
Author(s):  
Yuki Ebisawa ◽  
Rika Ohashi ◽  
Toshiya Takahashi ◽  
Takahiko Miura ◽  
Toshikazu Takizawa ◽  
...  
Keyword(s):  
Plasma Exchange ◽  
Thrombotic Thrombocytopenic Purpura ◽  
Steroid Therapy ◽  
High Dose ◽  
Thrombocytopenic Purpura ◽  
High Dose Steroid

Thrombotic Thrombocytopenic Purpura Resistant to Plasma-exchange: Salvage Treatment with High-dose IgG or Vincristine

1993 ◽  
Vol 16 (5_suppl) ◽  
pp. 201-204 ◽  
Author(s):  
C. Porta ◽  
E. Bobbio-Pallavicini ◽  
R. Centurioni ◽  
F. Tacconi ◽  
Keyword(s):  
Complete Remission ◽  
Plasma Exchange ◽  
Thrombotic Thrombocytopenic Purpura ◽  
Clinical Symptoms ◽  
Salvage Treatment ◽  
High Dose ◽  
Thrombocytopenic Purpura

Even though plasmaexchange (PE), either alone or combined with cortisone or platelet anti-aggregating substances is the treatment of choice for TTP, 10-15% of patients is resistant to treatment. Since immunoglobulin (IgG) infusion was reported to cure the clinical symptoms of PE-resistant TTP, and vincristine (VCR) has been recently successful in treating TTP, we reviewed the results obtained with both drugs in 20 PE-resistant patients. Of 12 patients receiving IgG and 8 receiving VCR, 3 (25%) and 4 (50%), respectively, achieved complete remission. Even though no conclusions can be drawn from such results, if complete remission can be achieved in a however small number of PE-resistant patients, the use of these drugs is suggested as a salvage treatment for TTP.

scholarly journals Elevated platelet-bound IgG associated with an episode of thrombotic thrombocytopenic purpura

Blood ◽  
1981 ◽  
Vol 58 (4) ◽  
pp. 682-684 ◽  
Author(s):  
PJ Sims ◽  
EB Boswell
Keyword(s):  
Plasma Exchange ◽  
Thrombotic Thrombocytopenic Purpura ◽  
Successful Treatment ◽  
Combined Therapy ◽  
Complete Recovery ◽  
Antiplatelet Drugs ◽  
High Dose ◽  
Normal Range ◽  
Thrombocytopenic Purpura

Abstract The level of platelet-associated IgG (PAIgG) were measured during the successful treatment of a patient with thrombotic thrombocytopenic purpura. Prior to therapy. PAIgG was found to be markedly elevated to 195 fg/cell (normal range 0--3.5 fg/cell). The institution of combined therapy with intensive plasma exchange transfusions, high-dose steroids, and antiplatelet drugs resulted in a complete recovery and a decline in PAIgG to the normal range. The possible role of platelet antibody in the pathogenesis of this disorder is discussed.

scholarly journals Relapse of Immune Thrombotic Thrombocytopenic Purpura Following Vaccination with COVID19 mRNA Vaccine

TH Open ◽  
2021 ◽  
Vol 05 (03) ◽  
pp. e335-e337
Author(s):  
Katerina Pavenski
Keyword(s):  
Case Report ◽  
Plasma Exchange ◽  
Thrombotic Thrombocytopenic Purpura ◽  
Previous History ◽  
Therapeutic Plasma Exchange ◽  
Patient Treatment ◽  
High Dose ◽  
Thrombocytopenic Purpura ◽  
History Of

AbstractAn 84 year old male with a previous history of immune thrombotic thrombocytopenic purpura (iTTP) received the first dose of COVID19 mRNA vaccine (Pfizer-Biontech). Seven days later he was diagnosed with iTTP relapse. He received in-patient treatment with therapeutic plasma exchange, high dose steroids and rituximab and subsequently recovered. This case report highlights the need to monitor patients with iTTP following vaccination.

scholarly journals Elevated platelet-bound IgG associated with an episode of thrombotic thrombocytopenic purpura

Blood ◽  
1981 ◽  
Vol 58 (4) ◽  
pp. 682-684
Author(s):  
PJ Sims ◽  
EB Boswell
Keyword(s):  
Plasma Exchange ◽  
Thrombotic Thrombocytopenic Purpura ◽  
Successful Treatment ◽  
Combined Therapy ◽  
Complete Recovery ◽  
Antiplatelet Drugs ◽  
High Dose ◽  
Normal Range ◽  
Thrombocytopenic Purpura

The level of platelet-associated IgG (PAIgG) were measured during the successful treatment of a patient with thrombotic thrombocytopenic purpura. Prior to therapy. PAIgG was found to be markedly elevated to 195 fg/cell (normal range 0--3.5 fg/cell). The institution of combined therapy with intensive plasma exchange transfusions, high-dose steroids, and antiplatelet drugs resulted in a complete recovery and a decline in PAIgG to the normal range. The possible role of platelet antibody in the pathogenesis of this disorder is discussed.

Relapsed/refractory thrombotic thrombocytopenic purpura treated with N-acetylcysteine: a case report

2018 ◽  
Vol 63 (4) ◽  
pp. 122-124
Author(s):  
Sinan Demircioğlu ◽  
Ömer Ekinci ◽  
Ali Doğan ◽  
Cengiz Demir
Keyword(s):  
Case Report ◽  
Renal Impairment ◽  
Plasma Exchange ◽  
Thrombotic Thrombocytopenic Purpura ◽  
Treatment Options ◽  
Rare Condition ◽  
High Dose ◽  
Thrombocytopenic Purpura ◽  
Loss Of Response ◽  
Refractory Case

Thrombotic thrombocytopenic purpura is a rare condition that presents with microangiopathic haemolytic anaemia, thrombocytopaenia, fever, renal impairment and neurological symptoms. Plasma exchange is a lifesaving treatment for this condition. However, some cases may be non-responsive to plasma exchange, or loss of response may occur. Treatment options for refractory cases include high-dose corticosteroids, rituximab, vincristine, cyclophosphamide, splenectomy, bortezomib and N-acetylcysteine. We present a refractory case of thrombotic thrombocytopenic purpura responding to the last of these therapies.

scholarly journals Total Plasma Exchange for the Management of Thrombotic Thrombocytopenic Purpura in a 13-Year-Old Female – A Case Presentation

2021 ◽  
Vol 26 (3) ◽  
pp. 48-51
Author(s):  
Ioana Roxana Codru ◽  
Bogdan Ioan Vintilă ◽  
Alina Simona Bereanu ◽  
Alina Camelia Cătană ◽  
Mihai Sava
Keyword(s):  
Monoclonal Antibodies ◽  
Plasma Exchange ◽  
Thrombotic Thrombocytopenic Purpura ◽  
Neurological Impairment ◽  
Organ Damage ◽  
Biological Evaluation ◽  
High Dose ◽  
Severe Thrombocytopenia ◽  
Thrombocytopenic Purpura ◽  
First Line Therapy

Abstract Acquired thrombotic thrombocytopenic purpura (TTP) is a rare thrombotic microangiopathy, affecting preferentially young women in their fourth decade. Intensive care admission is often required due to organ dysfunction development risk and for specific critical care measures (Plasma Exchange-PEX). In this article, we will discuss our experience with PEX in the treatment of TTP. Case report: A previously healthy 13-year-old female presented with neurological impairment, and suspicion of stroke. The head computed tomography (CT) scan revealed absence of acute intracranian pathology, and biological evaluation displayed severe thrombocytopenia and haemolytic anemia. After 24 hours, the neurological symptoms were remitted and suspicion of thrombotic thrombocytopenic purpura was raised. The presence of ADAMTS-13 antibodies and Moschcowitz’s pentad confirmed the diagnosis. Discussions: The distinctiveness of this case lies in the development of the disease in a 13-year-old person, though TTP usually occurs after the age of 40. The exact cause of ADAMTS-13 low activity could not be established. The use of a high dose of steroids and of plasma exchange is considered to be the first line therapy, with the use of monoclonal antibodies in refractory cases, as it was in our case. Conclusions: The primary end points of our management was to prevent organ damage and to achieve a platelet count greater than 150 000 /µL, as well as a normal or an almost normal lactate dehydrogenase. We achieved this by using high dose corticosteroid therapy, filtration of approximately 50 liters of plasma in 14 PEX session and by administration of monoclonal antibodies.

Sign in / Sign up

Export Citation Format

Share Document